Drug Information Association Logo

Risk Management and Safety Communication Strategies

« Back to Listing


Risk Communication is increasingly important to everyone involved in the health care system, especially the patients whose lives we strive to improve.  This class will look at current initiatives and new strategies to advance the safe use of drugs through better communications in an attempt to maximize patient benefits while minimizing the risks of medicine use.

Course Level: Intermediate

What You Will Learn 

  • Current state of risk communication in the United States and new initiatives designed to improve communication to promote the safe use of drugs
  • How the US Risk Evaluation and Mitigation Strategies (REMS) compares with the European Union Risk Management Plan (EU-RMP)
  • New strategies to improve understanding of drug safety concerns among health care providers and to promote better communication to patients
  • How patients comprehend and follow specific instructions
  • Communicating during a crisis situation
  • Future of drug safety and risk communication

Who Should Attend 

Professionals who work in:

  • Clinical safety and pharmacovigilance
  • Regulatory affairs
  • Medical writing
  • Marketing and communications
  • Clinical health care
  • Drug safety surveillance

Learning Objectives 

At the conclusion of this course, participants should be able to:

  • Describe current risk communication strategies in the US
  • Compare and contrast the US Risk Evaluation and Mitigation Strategies (REMS) and the European Union Risk Management Plan (EU-RMP)
  • Explain new methods to improve the proper use of medicines to maximize patient benefit and minimize risk
  • Identify strategies in communication during a crisis situation
  • Discuss the future of drug safety and risk communication in the US

Contact Information 

Jessica McGrory at +1-215-442-6182 or Jessica.McGrory@diahome.org

Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.

« Back to Listing Back To Top